RhoBTB proteins constitute a subfamily of atypical members within the Rho fa mily of small guanosine triphosphatases (GTPases). Their most salient feature is their domain architecture: a GTPase domain (in most cases, nonfunctional) is followed by a prolinerich region, a tandem of 2 broadcomplex, tramtrack, bric à brac (BTB) domains, and a conserved Cterminal region. In humans, the RhoBTB subfamily consists of 3 isoforms: RhoBTB1, RhoBTB2, and RhoBTB3. Orthologs are present in several other eukaryotes, such as Drosophila and Dictyostelium, but have been lost in plants and fungi. Interest in RhoBTB arose when RHOBTB2 was identified as the gene homozygously deleted in breast cancer samples and was proposed as a candidate tumor suppressor gene, a property that has been extended to RHOBTB1. The functions of RhoBTB pro teins have not been defined yet, but may be related to the roles of BTB domains in the recruitment of cullin3, a component of a family of ubiquitin ligases. A model emerges in which RhoBTB proteins are required to maintain constant levels of putative substrates involved in cell cycle regulation or vesicle transport through targeting for degradation in the 26S proteasome. RhoBTB proteins are engrossing the list of Rho GTPases involved in tumorigenesis. Unlike typical Rho GTPases (usually overexpressed or hyperactive), RhoBTB proteins appear to play a part in the carcinogenic process through a mechanism that involves the decreased or abolished expression of the corresponding genes, or more rarely, mutations that result in impaired functioning of the protein, presumably leading to the accumulation of RhoBTB substrates and alterations of the cellular homeo stasis.
Introduction
Since the late 1970s, when the first gene involved in tumor development in human was cloned, more than 200 tumor-related genes have been identified. They constitute a heterogeneous group of regulators of physiological pro cesses that includes hormones, growth factors, receptors, cell adhesion molecules, signal transduction mediators, and transcription factors. Ras is the most widely stud ied oncogene in human carcinogenesis, and its discovery stimulated the search for Rasrelated genes. Today, the Ras superfamily constitutes a numerous group of small guano sine triphosphatases (GTPases) that comprises over 150 members in humans, but can be found in all eukaryotes [1, 2] .
The common feature of Rasrelated proteins is a ~20 kDa domain that, with few exceptions, binds and hydrolyzes GTP. Ras proteins act as molecular switches, cycling be tween an active GTPbound state and an inactive GDP bound state. Activation enables the GTPase to interact with a multitude of effectors that relay upstream signals to other components, eliciting diverse cellular responses. Two classes of molecules modulate the activation/inactiva tion cycle: guanine nucleotide exchange factors (GEF) and GTPaseactivating proteins (GAP). In addition, guanine nucleotidedissociation inhibitors regulate cycling of some GTPases between membranes and cytosol. The members of the Ras superfamily can be divided into several families based on sequence similarities, such as the extensively studied Ras, Rho, Rab, Arf, Ran, and Miro families [1, 2] , and broadly speaking, each family participates in the regulation of a major cellular process. Rho GTPases are major regulators of the actin fila ment system and consequently of all processes that depend on the reorganization of the actin cytoskeleton, but they also participate in signaling pathways that regulate gene expression, cell cycle progression, apoptosis, and tumori genesis [3] [4] [5] . Rho GTPases are being extensively studied in eukaryotes, from plants to mammals. In humans, the family comprises 21 members that have been grouped into subfamilies: Cdc42like (Cdc42, TC10, TCL, Chp/Wrch2, Wrch1), Raclike (Rac1-3, RhoG), Rholike (RhoA-C), Rnd (Rnd1-2, Rnd3/RhoE), RhoD (RhoD and Rif), RhoH/ TTF and RhoBTB (RhoBTB1-3) [4] . Although RhoBTB3
is frequently left outside because of its divergent GTPase domain, there is compelling architectural, phylogenetic, and possibly functional evidence for grouping this protein within the RhoBTB subfamily. The RhoBTB subfamily constitutes the most recent ad dition to the Rho family. It was identified during the study of Rhorelated proteinencoding genes in Dictyostelium discoideum [6] . Orthologs have been found in numerous eukaryote clades, but are absent in fungi, plants, and some metazoa [7] . RhoBTB proteins are remarkable for their un usual domain architecture: all RhoBTB proteins possess additional domains beyond the GTPase domain, in particu lar, a tandem of broad complex, tramtrack, bric à brac (BTB) domains (from the Drosophila transcription factors where the domain was first described) that explains the name given to the family and fully justifies their inclusion in the group of socalled atypical Rho GTPases [8] .
Interest in the RhoBTB subfamily arose when RHOBTB2, the gene encoding the homonymous protein, was identified as the gene homozygously deleted in breast cancer samples and was proposed as a candidate tumor suppressor gene, dubbed DBC2 (deleted in breast cancer 2) [9] . The same property has been attributed recently to RHOBTB1 [10] . RhoBTB proteins can be therefore incorpo rated into the group of Rho GTPases involved in tumori genesis, although the mechanism RhoBTB proteins use differs radically from those of more typical Rho proteins [11] and may involve the direct targeting of other proteins for degradation in the 26S proteasome. In this review we will summarize what we know about RhoBTB proteins, starting with basic aspects, such as do main architecture and gene expression, followed by the ev idence that has accumulated during the last few years link ing RhoBTB proteins with cancer. We will then connect this information with the roles that emerge from functional studies performed on the mammalian, and more limited, slime mold and Drosophila orthologs. We will close this review with an attempt to integrate all the available struc tural and functional information into a model that explains the participation of RhoBTB proteins in tumorigenesis.
Structure of RhoBTB proteins
The most salient feature of RhoBTB proteins is their domain architecture, which is, in general terms, shared by all members of the subfamily. In these proteins, the GTPase domain is followed by a prolinerich region, a tandem of 2 BTB domains, and a conserved Cterminal region ( Figure 1 ). As already mentioned, in humans, the RhoBTB subfamily is composed of 3 isoforms: RhoBTB1, RhoBTB2, and RhoBTB3. RhoBTB1 and RhoBTB2 are very similar to each other and to the Drosophila ortholog (DmRhoBTB), whereas RhoBTB3 and the Dictyostelium discoideum ortholog (RacA) are the most divergent mem bers. Here we will describe each domain and will discuss its functionality as well as some variations found in indi vidual members.
GTPase domain The GTPase domain is perhaps the region where most divergence is found among members of the RhoBTB subfamily. Early analyses revealed that this domain is typically Raclike in RacA and divergent, but recognizable as Rhorelated in RhoBTB1 and RhoBTB2 as well as in DmRhoBTB [6] . In RhoBTB3, the GTPase domain appears extensively erased, to the point that it is virtually unrecognizable as a GTPase. Only a short stretch at the end of the domain can be reliably aligned to the GT Pase domain of other subfamily members. Consequently, RhoBTB3 does not bind GTP in vitro (Berthold J et al, personal communication). In phylogenetic analyses, the GTPase domain of RacA groups together with GTPases of the Rac subfamily and all relevant residues for nucleotide binding and enzymatic activity are conserved. In RacA the socalled Rho insert, a hypervariable insertion character istic for Rho proteins, is shorter (6 amino acids) than the usual 13 amino acids of most Rac proteins. As far as it has been examined, the GTPase domain of RacA behaves like other Rac proteins (see functions of RhoBTB proteins be low). The GTPase domain of RhoBTB proteins other than RhoBTB3 and RacA also contains a Rho insert that is lon ger than usual (18 residues or more) and rich in charged residues. Moreover, the GTPase domain of these RhoBTB contains 2 insertions and 1 deletion, as well as a few devia tions from the GTPase consensus of most Rho GTPases [6] .
The insertions are placed immediately before (6 residues) and after (10 residues) the switch I. The deletion (2 resi dues) affects the phosphate/magnesium binding region 3 within the switch II; in particular, one of the deleted residues is the glutamine equivalent to Q61 in Ras. Also of importance, the glycine residue equivalent to G12 in Ras appears substituted by asparagine in RhoBTB1 and RhoBTB2 or threonine in DmRhoBTB. Because these 2 residues are essential for GTP hydrolysis, these proteins would predictably display impaired enzyme activity. In deed, using a blot overlay approach, Chang and coworkers have shown that the GTPase domain of RhoBTB2 appears not to bind GTP at all, although this aspect requires bio chemical confirmation [12] .
Proline-rich region The prolinerich region links the GTPase to the first BTB domain. Sequences rich in proline are very common recognition motifs involved in proteinprotein interactions. Among the modules that bind proline rich regions are the SH3 (Src homology 3) domain, the WW domain, the Ena/VASP homology 1 domain, profilin, the GYF domain, ubiquitin enzyme variant (UEV), and the cytoskeletonassociated protein glycinerich domain [13, 14] .
The prolinerich region of some RhoBTB proteins could act as a SH3 domainbinding site. The SH3 domain is of ten present in proteins involved in signal transduction and cytoskeleton organization. The PxxP motif (where x de notes any amino acid), initially described as the core bind ing motif of the SH3 domain, can be found in RhoBTB1, RhoBTB2, and DmRhoBTB, where the prolinerich region is prominent, and in RacA, but not in RhoBTB3 where this region is very poorly preserved. Subsequent analyses have defined proline-rich motifs for a number of different SH3 domains more precisely as +xΦPxΦP (class I ligands) and ΦPxΦPx+ (class II ligands; where Φ is a hydropho bic and + is in most cases a basic residue) [13, 15] . Interest ingly, RhoBTB1 and RhoBTB2 have a conserved class II motif. DmRhoBTB has a motif that matches the more recently recognized class III ligands with the (R/K)xx(K/R) sequence [14] . Nevertheless, albeit the sequence analysis strongly suggests that the prolinerich region of several RhoBTB proteins is a potential SH3 domainbinding site, this still needs to be verified experimentally. BTB domain The BTB domain, also known as a poxvirus and zinc finger domain, is an evolutionary con served domain that is widespread among eukaryotes. In humans, nearly 200 different proteins bear BTB domains, in most cases, in combination with other domains. Two of the accompanying domains are particularly frequent, the zinc finger (ZF) and the Kelch domain. BTB-ZF proteins constitute a large family of transcription factors, whereas BTB-Kelch proteins play roles in the dynamics of the actin cytoskeleton [16, 17] .
The BTB domain has been known for long time as a protein-protein interaction domain participating in ho momeric and heteromeric associations with other BTB domains [18] . More recently, a series of papers almost si multaneously identified this domain as a component of cullin3dependent ubiquitin ligase complexes [19] [20] [21] [22] . These complexes constitute a class of the very large family of ubiquitin ligases [23] , which catalyze the addition of ubiqui tin, a highly conserved 76amino acid globular protein, to a number of target proteins. This post-translational modifica tion labels proteins for degradation by the 26S proteasome, although other cellular functions not directly involving pro tein degradation are also controlled by this modification [24] .
Cullins (of which there are 7 in mammals) function as scaffolding proteins that bring together the ubiquitin conjugating enzyme and substraterecognition components. The core ligase of a cullindependent complex consists of a cullin protein that binds through its Cterminus the RING finger protein Roc1 (which recruits the ubiquitin-conjugat ing enzyme) and through its Nterminus, a linker protein.
An adaptor protein then acts as a bridge between the linker protein and the substrates. The complex is positively regu lated by covalent attachment of the Nedd8 ubiquitinlike protein to the cullin subunit. Each cullin family member interacts with a specific adaptor. The cullin1 and cullin7 complexes contain the Skp1 linker and an Fboxcontaining adaptor, whereas the cullin2 and cullin5 complexes contain the linker elongin C (along with elongin B) and a SOCS boxcontaining protein. The cullin3 complexes contain a BTB domainbearing protein that interestingly functions simultaneously as a linker and adaptor [25] .
Closer inspection of the structure of the BTB domain in comparison with that of Skp1 and elongin C revealed a similar folding, and predictably a common interface for interaction with the corresponding cullin, despite a low degree of primary sequence conservation. In fact, elongin C and Skp1 are now considered BTB proteins. The com mon folding of all these proteins consists of a 95 amino acid globular cluster of 5 αhelices flanked by 3 short β-strands. The BTB domains of the BTB-ZF, BTB-Kelch, and RhoBTB proteins contain an Nterminal extension that folds into 1 αhelix and 1 βstrand, and this extension me diates the formation of dimers and oligomers [17] .
The BTB domains of RhoBTB have some special fea tures. A tandem of 2 BTB domains as in RhoBTB is not frequently found within the BTB protein family. More over, the first BTB domain is bipartite, being interrupted by an extension of unknown function that varies in length and composition among RhoBTB proteins. In RhoBTB1, RhoBTB2, and DmRhoBTB the insertion is 3 times lon ger (up to 100 residues) than in RhoBTB3 and RacA, and is in all cases rich in charged residues. Because the BTB domains of RhoBTB are of the extended type, these pro teins are predicted to exist as dimers, and in fact, they are capable of forming homodimers and heterodimers (Berthold J et al, personal communication). The role of RhoBTB as components of the cullin3dependent complexes will be discussed below.
The C-terminal region Following the second BTB domain, there is a region conserved in all members of the RhoBTB subfamily that may constitute a novel domain, but has not been found so far in any other protein apart from RhoBTB. The core of the Cterminal domain consists of approximately 80 amino acids that predictably folds as 4 consecutive αhelices. The last helix ends close before the prenylation signal of RhoBTB3, but prolongs fur ther in a predicted βstrand in RhoBTB1, RhoBTB2, and DmRhoBTB [7] .
Although Rho GTPases typically bear a CAAX motif, only RhoBTB3 conserves this feature. This motif is rec ognized by a set of enzymes that introduce a posttrans lational modification, isoprenylation, responsible for the targeting of the modified protein to membranes. Closely upstream of this motif there is an additional cysteine resi due in RhoBTB3, which suggest that this protein might also be palmitoylated [7] . The presence of nuclear localization signals in the Cterminus of some members of the RhoBTB subfamily has been occasionally reported [8, 12] , but is contro versial because computer programs commonly used to pre dict these signals often yield inconsistent results. Unlike for many BTB proteins that function as transcription fac tors, there is no experimental evidence showing the nuclear localization of RhoBTB.
Expression of RHOBTB genes
Both in humans and mice, all 3 RHOBTB genes are rather ubiquitously expressed, although with notable differ ences in the pattern of tissue levels among the 3 genes. In humans, where expression has been studied using multiple tissue Northern dot blots and quantitative PCR [7, 26, 27] , RHOBTB1 showed high levels in skeletal muscle and placenta followed by the stomach, kidney, testis, adrenal gland, and uterus, whereas RHOBTB3 is highly expressed in the placenta, testis, pancreas, adrenal and salivary glands, and neural and cardiac tissues. RHOBTB2 is very weakly expressed, but relatively high levels were detected in neural and cardiac tissues. All 3 genes are expressed in fetal tissues. The expression pattern of the mouse counterparts has been analyzed in conventional Northern blots and is roughly comparable to that of the human genes [7] . Mouse RHOBTB1 is highly expressed in the heart, testis, and kid ney, and moderately in the uterus, liver, lung, stomach, pla centa, and skeletal muscle. Mouse RHOBTB3 is strongly expressed in the brain, heart, and uterus, and moderately in all other tissues. As in human tissues, RHOBTB2 is very weakly expressed in mouse tissues, with relatively higher expression levels in the brain. In addition, the expres sion of 1 or more RHOBTB genes has been reported in numerous human and mouse cell lines using RT-PCR. In Northern blot analyses, mouse RHOBTB3 and RHOBTB1 appear as single 5 kb transcripts, although in most tissues, a less prominent 4 kb RHOBTB1 transcript is also ex pressed. RHOBTB2 is equally expressed both as 4 kb and 5 kb transcripts. The 2 transcripts in these genes have been explained by the use of alternative promoters or by alterna tive splicing in the 5´UTR, but this issue has not been ad dressed and remains speculative [7] .
RHOBTB3 has been reported in RNA from whole mouse embryos in Northern blot analyses, where a tran script was detected from embryonic d 11.5, declining at d 17.5 [7] . RHOBTB2 has been reported in several fetal tissues using RT-PCR [28] . Using in situ hybridization, the high and specific expression of RHOBTB2 has been observed in the central and peripheral nervous system and compara tively weaker in the gut during mouse embryogenesis, but the mRNA becomes undetectable at embryonic d 18.5 [28] .
Although still limited, these data implicate RHOBTB genes in controlling developmental processes. With RHOBTB2 having been described as a tumor sup pressor gene involved in breast cancer, it was of interest studying the expression of this gene during mammogen esis. Using RT-PCR and Northern blot analysis, StPierre et al [28] found that during mammary gland development in mice, RHOBTB2 transcripts are expressed at low but constant levels. However, attempts to study the spatial pat tern of the expression of RHOBTB2 in the mammary gland using in situ hybridization were inconclusive because of undetectable mRNA levels. Our own attempts to study the expression of RHOBTB genes at the cellular level using in situ hybridization on adult mouse tissues were hampered by the very low mRNA levels of these genes. While the ex pression of RHOBTB2 was undetectable in all of the tissues analyzed, RHOBTB1 and RHOBTB3 mRNA were found in the endothelial cells of the heart as well as in spermatocytes and spermatides in the testis. Additionally, RHOBTB1 and RHOBTB3 messages were detected in large vessels of the kidney and brain, respectively (Berthold J et al, personal communication).
RhoBTB in cancer
Since the first report proposing RHOBTB2 as a tumor suppressor gene, evidence is accumulating in support of members of the RhoBTB subfamily being implicated in tumorigenesis ( Table 1 ). The RHOBTB2 gene was identi fied as the gene homozygously deleted at region 8p21 in breast cancer samples [9] . This is a region commonly as sociated with loss of heterozygosity (LOH) in a wide range of cancers. Hamaguchi and coworkers performed a rep resentational deletion analysis on a large sample of breast tumors using DNA markers for the 8p21 region and found that RHOBTB2 was homozygously deleted in 3.5% of the tumors. A mutation analysis revealed 2 somatic missense mutations in breast tumors and 2 more missense mutations each in a breast and a lung tumor cell line. The expression of RHOBTB2 appeared extinguished in approximately 42% of breast and 50% of lung cancer cell lines [9] . A more ex tensive mutation analysis of breast cancers revealed some polymorphisms as well as 2 novel somatic mutations in the promoter and 5´UTR of RHOBTB2 in sporadic tumors, but no additional mutations in the coding region of sporadic or familial cancers [29] .
In a study addressing RHOBT2 in bladder cancer, Knowles et al performed a LOH and mutation analysis on tumor samples and cell lines [30] . They found LOH in the target region in 42% of informative tumors. A sequence analysis revealed numerous polymorphisms and 1 mis sense somatic mutation. In addition, the expression of RHOBTB2 was found to be reduced by 2 to 20fold in 9 of 12 cell lines with predicted LOH in the region of interest. In a study on primary gastric cancers, LOH was found in 29% of tumors; a sequence analysis identified several poly morphisms and 1 more missense somatic mutation [31] .
In a recent study on head and neck cancer, RHOBTB1 has also been postulated as a tumor suppressor gene [10] .
The 10q21 region where the RHOBTB1 gene is located has been identified as a hotspot region in head and neck squa mous cell carcinomas (HNSCC) in a genomewide LOH analysis [32] . Focusing on RHOBTB1, Beder et al found a high frequency of LOH with a microsatellite marker lo cated in intron 7 of the gene [10] . In 12 of 52 tumor samples, LOH could be demonstrated, and interestingly, 4 samples showed LOH exclusively for the RHOBTB1 locus. Since almost 50% of the tumor samples were not informative in the LOH analysis, it is very likely that the RHOBTB1 locus is affected in a higher proportion of tumors. A muta tion analysis revealed 3 polymorphisms, but no pathogenic mutations. The expression of RHOBTB1 decreased in 37% of the samples analyzed, although it increased in 35%, but significantly, all low-expression samples for which infor mative allelic loss data were available displayed LOH. Although we still have limited information on the sta tus of RHOBTB genes in tumors, the picture that emerges from the reports discussed above is one of rare mutations but common reduced or extinguished expression. This ob servation can be made extensive to the third family mem ber, RHOBTB3. We have determined the expression of RHOBTB3 in an array of tumor tissues and their matched normal tissues and have found a moderate but significant decrease of RHOBTB3 expression in the breast, kidney, uterus, lung, and ovary tumors (Berthold J et al, personal communication). It appears that mechanisms other than mutations are more frequently implicated in the inactiva tion of these genes. One such mechanism may be promoter methylation. The hypermethylation of CpG islands results in the downregulation or complete abrogation of gene ex pression and is a frequent epigenetic alteration in primary tumors [33] . The promoter region of RHOBTB2 has a CpG island, and in RHOBTB1, the promoter region and exon 1 (an untranslated exon) have a high GC content and numer ous CpG motifs. Interestingly, the mutations found in the promoter and 5´UTR of RHOBTB2 in some breast tumors might affect the regulation of gene expression [29] . The -238G>A polymorphism abolishes a putative Sp11 binding site and creates an additional CpG dinucleotide. The -121C>T mutation abolishes binding sites for the transcrip tion factors E2F and snail, and the +48G>A mutation cre ates a putative binding site for the bZIP910 transcription factor. Clearly, future work should be directed to analyze this aspect of RHOBTB gene expression in tumor tissues and cell lines. Only changes identified either as mutations or as polymorphisms that could result in functional alterations are shown in the table. For details on addi tional polymorphisms found in these studies and for information on the methods employed in the analyses, see references. The genomic structure of the RHOBTB genes is described in Ramos et al [7] . Note that in the table exons are numbered from the first transcribed exon, whereas in Ramos et al. exon 1 was considered the exon with the ATG codon [7] . RHOBTB1 is placed in 10q21.2, RHOBTB2/DBC2 in 8p21.3 and RHOBTB3 in 5q15. HD, homologous deletion. LOH, loss of heterozygosity. NA, not analyzed. SSCP, single strand conformation polymorphism. *Not determined whether somatic or germ line mutation. **Polymorphism with possible effect.
Functions of RhoBTB
The role of RHOBTB genes as tumor suppressors, ini tially attributed to RHOBTB2, more recently to RHOBTB1, and probably extensively also to RHOBTB3, is receiving increasing support. Nevertheless, the mechanisms by which RhoBTB proteins exert this and other roles remain largely speculative. Siripurapu et al have taken a large scale approach to explore the roles of RHOBTB2 [34] . They constitutively expressed RHOBTB2 in HeLa cells, followed by silencing of the ectopic gene and then a microarray analysis. A comparison of the overexpressing and silenced samples revealed significant alterations in genes belonging to 2 networks: one that regulates cell growth through cell cycle control and apoptosis and one that is related to cyto skeleton and membrane trafficking. Although the approach used in this study is adventurous and rather artificial, evi dence is accumulating in support of the roles for RhoBTB proteins in the processes revealed by Siripurapu et al [34] .
The identification of RhoBTB2 as a component and sub strate of cullin3dependent ubiquitin ligase complexes was key for the mechanistic understanding of RhoBTB func tioning [35] . Although several potential roles of RhoBTB proteins are considered separately, they are probably inter related. It is also very likely that the function as adaptors of cullin3dependent ubiquitin ligases constitutes the un derlying mechanism for all other roles, therefore, it will be discussed first and more extensively.
RhoBTB as adaptors of cullin3-dependent ubiquitin ligases
The identification of the BTB domain as adaptor in cullin3dependent ubiquitin ligase complexes prompted Wilkins and coworkers to investigate whether RhoBTB2 may also take part in the formation of such complexes [35] .
They identified the Nterminal region of murine cullin3 as an interacting partner of RhoBTB2 in a yeast 2 hybrid screening [35] . RhoBTB2 interacts specifically with cullin3, but not other cullin family members in vivo; the interaction was mapped to the first BTB domain in a series of pull down experiments with deletion constructs. Wilkins et al also provided evidence that RhoBTB2 is itself a substrate for cullin3based ubiquitin ligase complexes, as treatment with proteasomal inhibitor MG132 or shRNA ablation of cullin3 resulted in increased levels of RhoBTB2, and RhoBTB2 was polyubiquitinylated by cullin3 complexes in vitro [35] . Our own unpublished data indicate that many of these properties are shared by all members of the RhoBTB subfamily, including RhoBTB3.
RHOBTB2 was proposed as a candidate tumor suppres sor gene based on the fact that its reexpression in T47D (a breast cancer cell line that lacks RHOBTB2 transcripts) caused growth inhibition, whereas the expression of the so matic mutant D299N did not have the same effect [9] . This mutation is placed in the first BTB domain immediately before the insertion. In fact, it is interesting that almost all missense mutations found in the RHOBTB2 locus reside in the first BTB domain of the protein (Figure 1 ). The ques tion arises whether one or more of those mutations result in impaired interaction with cullin3. This has been investi gated by Wilkins and coworkers who found that the Y284D mutant, but not the D299N and D368A mutants, failed to coimmunoprecipitate with cullin3, and consequently, had a longer halflife than the wildtype protein [35] . The Y284D mutation resides in the dimerization interface of the first BTB domain and could prevent proper folding. Analogous mutants have been shown to abrogate function by impair ing folding of the BTB domain, for example, in the tran scription factor PLZF [36] .
We have found a correlation in the expression changes between RHOBTB3 or RHOBTB1 and CUL3 in tumor tissues (Berthold J et al, personal communication), sup porting the view that RHOBTB genes and CUL3 may be coregulated and the role of RhoBTB in tumorigenesis is related to its role as adaptor for cullin3dependent ubiqui tin ligase complexes. There are approximately 200 genes encoding BTB proteins in the human genome, suggesting that a significant proportion of cullin3dependent com plexes might control the ubiquitinylation and degradation of cancerrelated proteins through multiple mechanisms. In fact, several BTB proteins have been found to be linked to tumorigenesis, although their roles in the formation of cullin3dependent complexes have generally not been ad dressed. To cite a few examples, the tumor suppressor gene HIC1 (hypermethylated in cancer 1) is located at a re gion of chromosome 17 that is frequently hypermethylated or deleted in human tumors. It works as a transcriptional repressor functionally cooperating with p53 to suppress the agedependent development of cancer [37] . The tran scriptional repressor and candidate oncogene Bcl6 is an important regulator of lymphoid development and function. The BCL6 gene is localized in a region implicated in chro mosomal translocations frequently found in nonHodgkin' s lymphoma of Bcell type [38] . The Kelchrelated Mayven has been proposed to promote tumor growth through the induction of cJun and cyclin D1 [39] . Another example is Kaiso, involved in p120catenin/Kaiso signaling pathways that regulate gene expression in development and carcino genesis [40] . In fact, the role of cullin3dependent complexes in tumorigenesis can be placed in the wider context of the cullin family where every member has been found to be implicated in ubiquitinylation of cancerrelated substrates (see Guardavaccaro and Pagano [41] for a comprehensive re view). RhoBTB, cell growth, and apoptosis As already men tioned, Hamaguchi and coworkers reported that the overex pression of RhoBTB2 in the breast cancer cell line T47D ef fectively suppressed cell growth in vitro [9] . More recently,
Freeman and coworkers have shown that the overexpres sion of RhoBTB2 leads to a shortterm increase in cell cy cle progression and proliferation, but longterm expression has a negative effect on proliferation [42] . The growth arrest effect of RhoBTB2 has been explained by the downregula tion of cyclin D1. Cyclin D1 is upstream of cyclin E, and the overexpression of any of both prevented the growth arrest effect of RhoBTB2 [43] . The effect on cyclin D1 is probably posttranscriptional, but only partially dependent on proteasomal degradation. Moreover, it has not been investigated whether cyclin D1 is degraded by cullin3 dependent complexes through direct binding to RhoBTB2.
In this respect it is important to note that one mechanism as to how cullin3dependent complexes regulate the cell cycle is through the targeting of cyclin E for ubiquitinylation [44] .
The downregulation of cyclin D1 is essential for the cell proliferation suppression effect of RhoBTB2, but this works for T47D cells and not for 293 cells. It therefore appears that the regulation of cyclin D1 is not a universal tumor suppressive mechanism used by RhoBTB2. The ex planation has been put forward that resistance to RhoBTB2 in some cell lines may be achieved by rapid destruction of the protein through 26S proteasomemediated degrada tion [45] . Further support for the roles in cell cycle regula tion has been provided recently with the identification of RHOBTB2 as a target of the E2F1 transcription factor [42] .
E2F1 is a member of a class of E2F implicated in the transcription of genes necessary for DNA replication and cell cycle progression and can also promote apoptosis [46] .
RhoBTB2 levels increase upon initiation of prophase and decrease at telophase, and this effect depends on E2F1 [42] .
RhoBTB2 levels also increase during druginduced apoptosis in an E2F1dependent manner, and the down regulation of RHOBTB2 delays the onset of apoptosis [42] .
In agreement with an implication in this process, RhoBTB was found in Drosophila as one of several genes whose expression was significantly upregulated in a DNA micro array analysis aimed at identifying genes associated with cell death induced by the steroid hormone ecdysone [47] .
Interestingly, in this study, additional genes encoding Rho signaling components, most notably Rac2, also appeared upregulated. However, the role of RhoBTB as a candidate cell death regulator was not investigated further. RhoBTB and vesicle transport C h a n g e t a l have addressed the potential role of RhoBTB2 in vesicle transport in a fluorescent recovery after photobleaching analysis with the help of a vesicular stomatitis virus gly coprotein (VSVG) fused to GFP [12] . VSVG is extensively used to study anterograde transport from the endoplasmic reticulum to the Golgi apparatus. Knockdown of en dogenous RhoBTB2 hindered the ER to Golgi apparatus transport and resulted in the altered distribution of the fusion protein. In this study, the authors found that GFP -RhoBTB2 was distributed in a vesicular pattern when expressed at low levels. Some of the vesicles appeared adjacent to microtubules and an intact microtubule network seemed to be required for the mobility of RhoBTB. The localization of RhoBTB1 and RhoBTB2 in vesicu lar structures had been postulated before. Aspenström and coworkers reported the accumulation of the ectopically expressed proteins at perinuclear structures that did not colocalize with lysosomal or Golgi apparatus markers [48] .
These structures apparently represent aggregates, and can be also induced upon the ectopic expression of RhoBTB3. However, when RhoBTB3 is expressed at moderate lev els, it displays a vesicular pattern. Many of the vesicles colocalize with early endosome markers, and localization in close vicinity of microtubules is also apparent. As men tioned earlier, RhoBTB3 ends with a prenylation motif, and the Cterminal extension of RhoBTB3 is necessary and suf ficient for the attaching of the protein to vesicles (Berthold J et al, personal communication). However, prenylation might not be the only mechanism required for the targeting of RhoBTB to vesicles as RhoBTB1 and RhoBTB2 lack a prenylation motif. Further, in support of a role in vesicle trafficking, RhoBTB has been identified as one of the genes that sup press the neuromuscular junction overgrowth phenotype induced in Drosophila larvae by the expression of a domi nant negative form of the Nethylmaleimide sensitive fac tor (NSF) [49] . NSF is an ATPase that participates in vesicle trafficking through binding to the SNARE complex and is also important for the regulation of receptor trafficking [50] .
Interestingly, NSF is one gene whose expression appeared altered in the study of Siripurapu et al discussed earlier [34] , which is suggestive of a conserved mechanism that requires further investigation. If a role for these proteins in vesicle trafficking gains support, then RhoBTB will engross the growing list of Rho GTPases involved in this process. The mechanism remains obscure, but will be most likely an un usual one. RhoBTB and the actin filament system Although very atypical, RhoBTB proteins are members of the Rho family, therefore, the first aspect that was investigated was their effect on the organization of the actin filament system. Aspenström and coworkers observed a moderate influence, if at all, on the morphology and actin organization of por cine aortic endothelial cells upon the ectopic expression of RhoBTB1 and RhoBTB2 [48] , an observation that we have made extensive to RhoBTB3 and several other cell lines (Berthold J et al, personal communication). Not surpris ingly, neither RhoBTB1 nor RhoBTB2 were found to in teract with the GTPasebinding domain of WASP, PAK1, or Rhotekin, 3 wellknown effectors of many typical Rho GTPases [48] . Confirming that, at least in metazoa, RhoBTB proteins do not play a major role in the organization of the actin filament system, DmRhoBTB was found among the proteins whose depletion had no effect on lamellae morphology in Drosophila S2 cells [51] . These cells can be induced to spread when plated on a concanavalin Acoated surface and constitute then an appropriate system to study the formation of lamellae. Unlike metazoan RhoBTB, the Dictyostelium ortholog RacA may be directly implicated in the regulation of the actin cytoskeleton, although the evidence is indirect and no functional studies have been published yet. The racA gene is very weakly expressed throughout the life cycle of Dictyostelium [6] , but the protein is present at all stages.
The GTPase domain of RacA, which as already mentioned, is very closely related to members of the Rac subfamily, is able to interact with the Racbinding domain of WASP and kinases of the PAK family in yeast 2 hybrid assays [52] [53] [54] , although these interactions remain to be demonstrated in vivo. Unlike metazoan RhoBTB, RacA is susceptible to regulation by RhoGEF and RhoGAP, and in vitro interac tion with a RhoGEF, GxcDD, has been reported recently [55] . We speculate that RacA represents a "primitive" cytoskele tonregulating stage of the RhoBTB subfamily that was re placed in the evolved metazoan RhoBTB proteins by roles in cell proliferation and vesicle trafficking.
Conclusion
There is increasing evidence linking Rhoregulated signal transduction pathways to tumorigenesis and me tastasis [11, 56, 57] . Rho GTPases play a role in the acquisition of an invasive phenotype of tumor cells, either directly via their effects on the cytoskeleton, or indirectly via changes in gene transcription. It is noteworthy that with the excep tion of RacH and perhaps Rac1, no mutations in typical Rho GTPases have been found to be associated specifically Figure 2 . Model of the mechanism of action of mammalian RhoBTB. RhoBTB proteins recruit cullin3 (regulated by the attachment of Ned8), Roc, and the E2 (ubiquitinconjugating enzyme) component of the ubiquitinylation pathway to constitute an ubiquitin ligase. E1 is the ubiquitin activating enzyme. RhoBTB proteins most probably function as dimers, but for simplicity, this aspect is not shown in the model. Interaction with cullin3 takes place through the first BTB domain. GTPase and other domains as well as the insertion of the first BTB domain could function as substrate recognition domains. Pro linerich region is a potential SH3binding domain in several but not all RhoBTB proteins. Note also that RhoBTB proteins become autoubiquitinylated (not depicted). Substrates may be involved in regulating cell growth and vesicle trafficking, and would be kept at low levels by degradation in the 26S proteasome. Reduced expression of RhoBTB or mutations that impair formation of the complex would result in the accumulation of the substrates and contribute to tumor formation or progression.
with tumors. It is rather alterations in the expression or activation levels of these proteins which characterizes many tumors. For example, the expression of Rac1b (an alterna tive splice variant of Rac1) increases in colorectal tumors [58] , the overexpression of RhoC correlates with the invasive ness of nonsmall cell lung cancer [59] , and Cdc42 is overex pressed in HNSCC [60] .
Unlike typical Rho GTPases, those of the RhoBTB subfamily appear to play a part in the carcinogenic process through a mechanism that involves the downregulation or loss of function. Taking into consideration the ability of RhoBTB proteins to constitute cullin3dependent com plexes, a model emerges in which these proteins recruit substrates for degradation in the 26S proteasome ( Figure  2) . While the first BTB domain is involved in recruitment of cullin3 and associated components, other regions of the protein, such as the GTPase domain and the Cterminal conserved region or even the second BTB domain, would function as substrate recognition domains. The insertion of the first BTB domain probably folds away from the globu lar BTB core and might also be implicated in substrate rec ognition, whereas the prolinerich region of RhoBTB1 and RhoBTB2 could play regulatory roles through interaction with SH3 domainbearing proteins.
RhoBTB proteins would be required to maintain con stant levels of putative substrates, thus exerting regulatory roles during the cell cycle, vesicle transport, and in lower eukaryotes, cytoskeleton homeostasis. It is easy to under stand that situations that result in the impaired expression of RHOBTB genes, or more rarely, mutations that result in impaired functioning (binding to cullin3, dimerization, interaction with substrates, targeting) of the protein might lead to the accumulation of RhoBTB substrates and altera tions of the cellular homeostasis. Such a regulatory mech anism could be the basis of the tumor suppressor role of RhoBTB proteins and is analogous to the wellstudied role of the von Hippel-Lindau (VHL) tumor suppressor. VHL is an adaptor for cullin2dependent ubiquitin ligase com plexes that target the hypoxiainducible factor for degrada tion. Nearly 70% of naturallyoccurring cancerpredispos ing mutations of VHL disrupt the formation of these com plexes [61] . Obviously, if we wish to clear the mechanisms as to how the malfunction of RhoBTB proteins results in tumor formation, we imperatively need to know how these proteins are regulated at all levels (transcriptional, transla tional, and posttranslational) and what their substrates are.
